Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 14, Number 7—July 2008

Research

Toxinotype V Clostridium difficile in Humans and Food Animals

Michael A. Jhung*Comments to Author , Angela D. Thompson*, George E. Killgore*, Walter E. Zukowski†, Glenn Songer‡, Michael Warny§, Stuart Johnson†¶, Dale N. Gerding†¶, L. Clifford McDonald*, and Brandi M. Limbago*
Author affiliations: *Centers for Disease Control and Prevention, Atlanta, Georgia, USA; †Hines Veterans Affairs Hospital, Chicago, Illinois, USA; ‡University of Arizona, Tucson, Arizona, USA; §Acambis, Inc., Cambridge, Massachusetts, USA; ¶Loyola University Chicago Stritch School of Medicine, Chicago;

Main Article

Table 2

Antimicrobial drug susceptibility of toxinotype V Clostridium difficile isolates, 1989–2006*

Source N Clindamycin
Levofloxacin†
Moxifloxacin
Gatifloxacin†
S I/R Range S I/R Range S Range S Range
Human 14 2 (14) 12 (86) 2–>256 6 (43) 8 (57) 2–>32 14 (100) 0.5–1 14 (100) 0.5–1
Recent 7 2 (29) 5 (71) 2–>256 0 7 (100) >32 7 (100) 0.5 7 (100) 0.5–1
Past
7
0
7 (100)
4–>256

7 (100)
0
2–4

7 (100)
0.5–1

7 (100)
0.5–1
Porcine 8 0 8 (100) 4-–>256 2 (25) 6 (75) 2–>32 8 (100) 0.5–1 8 (100) 0.5–1
Bovine 8 7 (88) 1 (12) 1–4 8 (100) 0 2–4 8 (100) 0.5 8 (100) 0.5

*No. (%) Clostidium difficile isolates shown in each interpretive category. S, susceptible; I/R, intermediate or resistant.
†Using moxifloxacin interpretive criteria.

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO